^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

Venclexta (venetoclax)

i
Other names: ABT-199, RG 7601, GDC-0199, RG7601, RG-7601, GDC 0199, A-1195425.0, ABT199, ABT 199, RO-5537382, ABT-0199
Company:
AbbVie, Roche, Walter and Eliza Hall Institute
Drug class:
Bcl2 inhibitor
Related drugs:
12h
Effective Targeting of Melanoma Cells by Combination of Mcl-1 and Bcl-2/Bcl-xL/Bcl-w Inhibitors. (PubMed, Int J Mol Sci)
Thus, we investigated the effects of ABT-737 and ABT-263, which target Bcl-2, Bcl-xL and Bcl-w as well as the Bcl-2-selective ABT-199 and the Mcl-1-selective S63845, in a panel of four BRAF-mutated and BRAF-WT melanoma cell lines. These findings demonstrate that melanoma cells can be efficiently targeted by BH3 mimetics, but the right combinations have to be selected. The observed pronounced activation of apoptosis pathways demonstrates the decisive role of apoptosis in the loss of cell viability by BH3 mimetics.
Journal • IO biomarker
|
BRAF (B-raf proto-oncogene) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • BCL2L2 (BCL2 Like 2) • XIAP (X-Linked Inhibitor Of Apoptosis)
|
BRAF mutation • BRAF wild-type
|
Venclexta (venetoclax) • navitoclax (ABT 263) • S63845 • ABT-737
16h
Venetoclax Resistance in Acute Myeloid Leukemia. (PubMed, Cancers (Basel))
Venetoclax combined with azacitidine (VEN-AZA) has become a new standard treatment for AML patients unfit for intensive chemotherapy. Strategies to overcome venetoclax resistance are being developed in clinical trials, including triplet therapies with targeted agents targeting IDH, FLT3, as well as the recently developed menin inhibitors or immunotherapies such as antibody-drug conjugated or monoclonal antibodies. A better understanding of the molecular factors driving venetoclax resistance by single-cell analyses will help the discovery of new therapeutic strategies in the future.
Review • Journal • IO biomarker
|
TP53 (Tumor protein P53) • FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
|
Venclexta (venetoclax) • azacitidine
17h
Molecular ontogeny underlies the benefit of adding venetoclax to hypomethylating agents in newly diagnosed AML patients. (PubMed, Leukemia)
The OS benefit of HMA + VEN in secondary ontogeny was similar in those with vs. without splicing mutations (P = 0.92). Secondary ontogeny AML highlights a group of patients whose disease is selectively responsive to VEN added to HMA and that the addition of VEN has no clinical benefit in TP53-mutated AML.
Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax)
17h
Olutasidenib in post-venetoclax patients with mutant isocitrate dehydrogenase 1 (mIDH1) acute myeloid leukemia (AML). (PubMed, Leuk Lymphoma)
Safety was consistent with the overall profile of olutasidenib. Olutasidenib offers a valuable treatment option for patients with mIDH1 AML previously treated with venetoclax.
Journal
|
IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
|
IDH1 mutation
|
Venclexta (venetoclax) • Rezlidhia (olutasidenib)
1d
Safety and Efficacy of Venetoclax in Idiopathic Pulmonary Fibrosis (clinicaltrials.gov)
P1, N=3, Completed, University of Alabama at Birmingham | Recruiting --> Completed
Trial completion • IO biomarker
|
Venclexta (venetoclax)
1d
Therapeutic targeting of apoptosis in chronic lymphocytic leukemia. (PubMed, Semin Hematol)
In contrast, relapsed CLL that arises while being off therapy after a period of time-limited venetoclax-based regimens maintains sensitivity to re-treatment with venetoclax for the majority of patients. Novel strategies related to therapeutic targeting of apoptosis include next-generation BCL-2 inhibitors with improved potency and pharmacokinetic profiles, direct targeting of anti-apoptotic BH3 family proteins beyond BCL-2 such as MCL-1, and indirect targeting of MCL-1 through mechanisms such as small molecule cyclin-dependent kinase 9 inhibitors.
Journal • IO biomarker
|
TP53 (Tumor protein P53) • IGH (Immunoglobulin Heavy Locus) • CDK9 (Cyclin Dependent Kinase 9)
|
TP53 mutation • BCL2 mutation
|
Venclexta (venetoclax)
1d
A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. (PubMed, Blood Adv)
In this multicenter, retrospective study, we evaluated 62 patients with RT who received venetoclax-based treatment outside of a clinical trial, in combination with a Bruton tyrosine kinase inhibitor (BTKi; n=28), R-CHOP (n=13), or intensive chemoimmunotherapy other than R-CHOP (n=21). Grade 3-4 neutropenia and thrombocytopenia events were most frequent with intensive chemoimmunotherapy + venetoclax; grade 3-4 infection rates were similar across treatment groups. In this difficult-to-treat RT patient population, venetoclax-based combination regimens achieved high response rates, with durable remission and survival observed in a subset of patients.
Clinical • Journal • IO biomarker
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • Rituxan (rituximab)
1d
PROTAC-Mediated Dual Degradation of BCL-xL and BCL-2 Is a Highly Effective Therapeutic Strategy in Small-Cell Lung Cancer. (PubMed, Cells)
In our previous study, the first-in-class BCL-xL PROTAC, called DT2216, was shown to have synergistic antitumor activities when combined with venetoclax (formerly ABT199, BCL-2-selective inhibitor) in a BCL-xL/2 co-dependent SCLC cell line, NCI-H146 (hereafter referred to as H146), in vitro and in a xenograft model. At this dosage, 753b was well tolerated in mice, without observable induction of severe thrombocytopenia as seen with navitoclax, and no evidence of significant changes in mouse body weights. These results suggest that the BCL-xL/2 dual degrader could be an effective and safe therapeutic for a subset of SCLC patients, warranting clinical trials in future.
Journal
|
BCL2 (B-cell CLL/lymphoma 2) • BCL2L1 (BCL2-like 1)
|
Venclexta (venetoclax) • navitoclax (ABT 263) • DT2216
2d
SLSG18-301: Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2 (clinicaltrials.gov)
P3, N=126, Active, not recruiting, Sellas Life Sciences Group | Recruiting --> Active, not recruiting
Enrollment closed
|
Venclexta (venetoclax) • cytarabine • azacitidine • decitabine • Zeltherva (galinpepimut-S) • hydroxyurea • Leukine (sargramostim)
3d
Low expression of miR-182 caused by DNA hypermethylation accelerates acute lymphocyte leukemia development by targeting PBX3 and BCL2: miR-182 promoter methylation is a predictive marker for hypomethylation agents + BCL2 inhibitor venetoclax. (PubMed, Clin Epigenetics)
Collectively, we identified miR-182 as a tumor suppressor gene in ALL cells and low expression of miR-182 because of hypermethylation facilitates the malignant phenotype of ALL cells. DAC + Ven cotreatment might has been applied in the clinical try for ALL patients with miR-182 promoter hypermethylation. Furthermore, the methylation frequency at the miR-182 promoter should be a potential biomarker for DAC + Ven treatment in ALL patients.
Journal • IO biomarker • Epigenetic controller
|
ABL1 (ABL proto-oncogene 1) • BCR (BCR Activator Of RhoGEF And GTPase) • MIR182 (MicroRNA 182) • SPN (Sialophorin) • PBX3 (PBX Homeobox 3)
|
Venclexta (venetoclax)
3d
Cyclin dependent kinase 4/6 inhibitor palbociclib synergizes with BCL2 inhibitor venetoclax in experimental models of mantle cell lymphoma without RB1 deletion. (PubMed, Exp Hematol Oncol)
Our data strongly support investigation of the chemotherapy-free palbociclib and venetoclax combination as an innovative treatment strategy for post-ibrutinib MCL patients without RB1 deletion.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • RB1 (RB Transcriptional Corepressor 1) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
CDKN2A deletion • RB1 deletion • MYC expression • CDK4 overexpression • CDKN2A overexpression • RB deletion
|
Venclexta (venetoclax) • Ibrance (palbociclib) • Imbruvica (ibrutinib)
3d
Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies (clinicaltrials.gov)
P1/2, N=130, Recruiting, National Cancer Institute (NCI) | Trial primary completion date: Mar 2024 --> Mar 2025
Trial primary completion date
|
ALK (Anaplastic lymphoma kinase) • BCL2 (B-cell CLL/lymphoma 2)
|
MYC rearrangement
|
Venclexta (venetoclax) • enitociclib (VIP152)
3d
03-OHD-104: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML (clinicaltrials.gov)
P1, N=160, Recruiting, Shattuck Labs, Inc. | N=107 --> 160 | Trial completion date: Oct 2024 --> Dec 2025 | Trial primary completion date: Feb 2024 --> Apr 2025
Enrollment change • Trial completion date • Trial primary completion date • Combination therapy
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine • SL-172154
3d
Venetoclax in Combination With Decitabine and Cedazuridine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P2, N=20, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting
Enrollment closed • Combination therapy
|
Venclexta (venetoclax) • Inqovi (decitabine/cedazuridine)
3d
BRUIN: A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL (clinicaltrials.gov)
P1/2, N=860, Active, not recruiting, Loxo Oncology, Inc. | Trial completion date: Apr 2024 --> Jan 2028 | Trial primary completion date: Apr 2024 --> Sep 2027
Trial completion date • Trial primary completion date
|
Venclexta (venetoclax) • Rituxan (rituximab) • Jaypirca (pirtobrutinib)
3d
Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review (PubMed, Zhonghua Xue Ye Xue Za Zhi)
The patient with skin nodules and the pathology diagnosed BPDCN, the next generation sequencing of skin nodules showed mutations of IDH2 and ASXL1. DVT (decitabine combined with Venetoclax and thalidomide) has significant efficacy with rapid and deep remission for BPDCN, and the adverse effects is less, especially suitable for elderly patients who cannot tolerate intense chemotherapy.
Review • Journal
|
IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2) • ASXL1 (ASXL Transcriptional Regulator 1)
|
IDH2 mutation • ASXL1 mutation
|
Venclexta (venetoclax) • decitabine • thalidomide
4d
Synthesis of novel (R)-carvone-tagged thiazolidinone as anticancer leads: characterization, in vitro antiproliferative evaluation and in silico studies. (PubMed, J Biomol Struct Dyn)
MTT assay revealed promising results for compounds 5b and 5c, demonstrating good antiproliferative activity against A-549 and MCF-7 cell lines comparable to the positive control, Doxorubicin. In PAK4 assay, compound 5c showed comparable potency (IC50 6.76 µM) with the standard control UC2288 (IC50 6.40 µM), while in BCL-2 TR-FRET assay, 5c exhibited good inhibition (IC50 1.78 µM) as compared to Venetoclax (IC50 0.016 µM). In conclusion, compounds 5a-c could be used as a structural framework for the discovery of novel therapeutics to combat different types of cancer.Communicated by Ramaswamy H. Sarma.
Preclinical • Journal
|
BCL2 (B-cell CLL/lymphoma 2) • CDKN1A (Cyclin-dependent kinase inhibitor 1A)
|
Venclexta (venetoclax) • doxorubicin hydrochloride
4d
BCL-2 inhibition in haematological malignancies: Clinical application and complications. (PubMed, Blood Rev)
There are also clinical problems with BCL-2 family inhibition, including drug resistance, disease relapse, tumour lysis syndrome, and clinically relevant cytopenias. Here, we provide a balanced view on both the clinical benefits of BCL-2 inhibition as well as the associated challenges.
Review • Journal • IO biomarker
|
MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1)
|
MCL1 expression
|
Venclexta (venetoclax)
4d
New trial
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • cytarabine • etoposide IV • Synribo (omacetaxine mepesuccinate)
4d
Prognostication in chronic lymphocytic leukemia. (PubMed, Semin Hematol)
On the opposite side of the spectrum, IGHV mutated patients devoid of TP53 disruption benefit the most from fixed-duration therapy with venetoclax-obinutuzumab. In the context of the aggressive transformation of CLL, namely Richter syndrome, the clonal relationship to the CLL counterpart represents the strongest prognostic biomarker. Clonally related Richter syndrome still represents an unmet clinical need which requires further efforts to identify new therapeutic strategies.
Journal • IO biomarker
|
IGH (Immunoglobulin Heavy Locus)
|
TP53 mutation • IGH mutation
|
Venclexta (venetoclax) • Gazyva (obinutuzumab)
5d
Phase I Study of HC-7366 With Azacitidine and Venetoclax for Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center | N=58 --> 18
Enrollment change
|
Venclexta (venetoclax) • azacitidine • HC-7366
5d
Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes. (PubMed, Nat Commun)
While MDS HSCs in an undifferentiated cellular state are sensitive to venetoclax treatment, differentiation towards a granulo-monocytic-biased transcriptional state, through the acquisition or expansion of clones with STAG2 or RUNX1 mutations, affects HSCs' survival dependence from BCL2-mediated anti-apoptotic pathways to TNFα-induced pro-survival NF-κB signaling and drives resistance to venetoclax-mediated cytotoxicity. Our findings reveal how hematopoietic stem and progenitor cell (HSPC) can eventually overcome therapy-induced depletion and underscore the importance of using close molecular monitoring to prevent HSPC hierarchical change in MDS patients enrolled in clinical trials of venetoclax.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • RUNX1 (RUNX Family Transcription Factor 1) • TNFA (Tumor Necrosis Factor-Alpha) • STAG2 (Stromal Antigen 2)
|
RUNX1 mutation • STAG2 mutation
|
Venclexta (venetoclax)
6d
A Case of Relapsed/Refractory CD56-Positive Acute Promyelocytic Leukemia, in Which Complete Molecular Remission Was Achieved Following Combination Therapy with Venetoclax and Azacitidine. (PubMed, Gan To Kagaku Ryoho)
In August Year X-1, she developed molecular relapse and was started on tamibarotene(Am80). She died of gastrointestinal hemorrhage. This is considered a valuable case for accumulating information on the treatment of CD56-positive APL resistant to ATRA and ATO.
Journal • Combination therapy
|
RARA (Retinoic Acid Receptor Alpha) • NCAM1 (Neural cell adhesion molecule 1)
|
NCAM1 positive
|
Venclexta (venetoclax) • azacitidine • Amnolake (tamibarotene)
7d
New P2 trial • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2)
|
Venclexta (venetoclax) • Gazyva (obinutuzumab) • Itari (linperlisib)
7d
Study of Magrolimab Combinations in Participants With Myeloid Malignancies (clinicaltrials.gov)
P2, N=54, Completed, Gilead Sciences | Active, not recruiting --> Completed
Trial completion
|
Venclexta (venetoclax) • cytarabine • etoposide IV • mitoxantrone • magrolimab (GS-4721) • Onureg (azacitidine oral)
8d
Steroid-free combination of 5-azacytidine and venetoclax for the treatment of multiple myeloma. (PubMed, Haematologica)
Lastly, we show for the first time in primary MM patient samples, that 5-azacytidine enhances the response to venetoclax ex-vivo, across diverse anti-apoptotic dependencies (BCL-2 or MCL-1) and diverse cytogenetic backgrounds. Overall, our data identifies 5-azacytidine and venetoclax as an effective treatment combination and this could be a tolerable steroid-sparing regimen, particularly for elderly MM patients.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • PMAIP1 (Phorbol-12-Myristate-13-Acetate-Induced Protein 1)
|
Chr t(11;14) • BCL2 overexpression
|
Venclexta (venetoclax) • azacitidine
8d
Comprehensive analysis of m6A methylome alterations after azacytidine plus venetoclax treatment for acute myeloid leukemia by nanopore sequencing. (PubMed, Comput Struct Biotechnol J)
In conclusion, we illustrated for the first time the global landscape of m6A levels in AZA plus VEN treated AML (CR) patients and revealed that AZA had a significant demethylation effect at the RNA level in AML patients. In addition, we identified new biomarkers for AZA plus VEN-treated AML via Nanopore sequencing technology in RNA epigenetics.
Journal
|
HPRT1 (Hypoxanthine Phosphoribosyltransferase 1)
|
Venclexta (venetoclax) • azacitidine
8d
Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma (clinicaltrials.gov)
P2, N=23, Active, not recruiting, Emory University | Trial primary completion date: Sep 2023 --> Sep 2024
Trial primary completion date
|
CCND1 (Cyclin D1)
|
Chr t(11;14)
|
Venclexta (venetoclax) • Gazyva (obinutuzumab) • bendamustine
8d
VENETACIBLE: Plasma Dosage of Venetoclax in the Fup of AML Patients Treated With Aza + Ven (clinicaltrials.gov)
P=N/A, N=20, Recruiting, Centre Hospitalier Universitaire de Nice | Not yet recruiting --> Recruiting | Initiation date: Oct 2023 --> Feb 2024
Enrollment open • Trial initiation date
|
Venclexta (venetoclax) • azacitidine
8d
Inhibition of MALT1 and BCL2 induces synergistic anti-tumor activity in models of B cell lymphoma. (PubMed, Mol Cancer Ther)
We also identified a rational combination partner for ABBV-MALT1 in the BCL2 inhibitor, venetoclax, which when combined significantly synergizes to elicit deep and durable responses in preclinical models. This work highlights the potential of ABBV-MALT1 monotherapy and combination with venetoclax as effective treatment options for patients with ABC-DLBCL.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • MALT1 (MALT1 Paracaspase)
|
Venclexta (venetoclax)
9d
Azacitidine combined with venetoclax alleviates AML-MR with TP53 mutation in SDS: a case report and literature review. (PubMed, Anticancer Drugs)
He achieved complete remission with incomplete recovery and proceeded to Allo-HSCT. We hope to provide some evidence and insight for in-depth research and clinical treatment by presenting this case.
Review • Journal
|
TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax) • azacitidine
10d
New P2 trial • Tumor mutational burden
|
Venclexta (venetoclax) • Xospata (gilteritinib) • azacitidine
10d
New P2 trial • Combination therapy
|
MCL1 (Myeloid cell leukemia 1) • KMT2A (Lysine Methyltransferase 2A) • BCL2L1 (BCL2-like 1)
|
BCL2 expression
|
Venclexta (venetoclax) • cytarabine • doxorubicin hydrochloride • cyclophosphamide • Blincyto (blinatumomab) • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Asparlas (calaspargase pegol-mknl) • Rylaze (recombinant Erwinia asparaginase) • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate)
10d
ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. (PubMed, Oncotarget)
Enhanced activation of apoptosis was observed in leukemia patient-derived cell samples exposed to the five-drug combination, suggesting a clinical relevance. The results provide a rationale for clinical trials using these two- and five-drug combinations as part of a conditioning regimen for AML patients undergoing HSCT.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • BCL2 (B-cell CLL/lymphoma 2) • MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • CHEK2 (Checkpoint kinase 2) • CHEK1 (Checkpoint kinase 1) • CASP3 (Caspase 3) • ANXA5 (Annexin A5) • HSP90AA1 (Heat Shock Protein 90 Alpha Family Class A Member 1Heat Shock Protein 90 Alpha Family Class A Member 1)
|
Venclexta (venetoclax) • cladribine • fludarabine IV • thiotepa • busulfan
11d
NCI-2019-03272: Ruxolitinib and Venetoclax in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia (clinicaltrials.gov)
P1, N=31, Active, not recruiting, Brian Druker | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy
|
Venclexta (venetoclax) • Jakafi (ruxolitinib)
11d
Investigations of the prognostic value of RUNX1 mutation in acute myeloid leukemia patients: Data from a real-world study. (PubMed, Leuk Res)
In those who received venetoclax plus hypomethylating agents, RUNX1mut was not predictive of CRc and comparable OS and EFS were seen between intermediate-risk and adverse-risk groups...Its prognostic value depended more on treatment and co-occurrent abnormalities. VEN-HMA may abrogate the prognostic impact of RUNX1, which merits a larger prospective cohort to illustrate.
Journal • Real-world evidence • Real-world
|
RUNX1 (RUNX Family Transcription Factor 1)
|
RUNX1 mutation
|
Venclexta (venetoclax)
11d
C/EBPα-p30 confers AML cell susceptibility to the terminal unfolded protein response and resistance to Venetoclax by activating DDIT3 transcription. (PubMed, J Exp Clin Cancer Res)
Our results indicate that AML patients with a low C/EBPα p42/p30 ratio (e.g., CEBPAbi) may not benefit from monotherapy with BCL2 inhibitors. However, this issue can be resolved by combining ER stress inducers.
Journal • IO biomarker
|
CEBPA (CCAAT Enhancer Binding Protein Alpha) • DDIT3 (DNA-damage-inducible transcript 3)
|
Venclexta (venetoclax) • sorafenib
12d
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • CD38 (CD38 Molecule) • CD123 (Interleukin 3 Receptor Subunit Alpha) • IL3RA (Interleukin 3 Receptor Subunit Alpha)
|
BCL2 expression
|
Venclexta (venetoclax) • Darzalex (daratumumab) • Elzonris (tagraxofusp-erzs)
14d
Mitoxantrone Hydrochloride Liposome Combined With Chemotherapy in Untreated de Novo Acute Myeloid Leukemia (clinicaltrials.gov)
P=N/A, N=90, Recruiting, Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting --> Recruiting
Enrollment open
|
Venclexta (venetoclax) • cytarabine • Synribo (omacetaxine mepesuccinate) • Duoenda (mitoxantrone liposomal)
14d
Enrollment closed • Enrollment change
|
FLT3 (Fms-related tyrosine kinase 3)
|
FLT3-ITD mutation • FLT3 mutation • FLT3 D835
|
Venclexta (venetoclax) • Xospata (gilteritinib)
14d
New P2 trial
|
BRAF (B-raf proto-oncogene) • TP53 (Tumor protein P53)
|
TP53 mutation
|
Venclexta (venetoclax)
14d
Trial completion date • Combination therapy
|
Venclexta (venetoclax) • Imbruvica (ibrutinib)